CA224

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: CA224
• 英文别名: biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)ethyl]methylamide；biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methyl-amide；N-[2-(1H-Indol-3-yl)ethyl]-N-methyl-4-phenylbenzamide
• 化学式: C₂₄H₂₂N₂O
• 分子量: 354.451
• InChiKey: CPKLVRIYXBROSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  36.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  ethyl 2-(1H-indole-3-yl)ethylcarbamate 在 sodium hydroxide 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.08h， 生成 CA224
  参考文献：
  名称：

  Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin

  摘要：

  我们介绍了三类色胺衍生物的设计、合成及其生物活性，这些衍生物是非平面型的毒性抗癌剂fascaplysin的类似物。我们表明这些化合物是CDK4相对于CDK2的选择性抑制剂，活性最强的化合物9q对CDK4的抑制作用具有6 µM的IC50值。

  DOI：

  10.1039/b518019h

文献信息

• [EN] FUNCTIONALIZED AZABORINE COMPOUNDS AND AZABORINE-CONTAINING BIARYLCARBOXAMIDES, AND COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSÉS D'AZABORINE FONCTIONNALISÉS ET BIARYLCARBOXAMIDES CONTENANT DE L'AZABORINE, ET LEURS COMPOSITIONS ET PROCÉDÉS
  申请人：TRUSTEES BOSTON COLLEGE

  公开号：WO2015160688A1

  公开（公告）日：2015-10-22

  The invention provides novel azaborine compounds, methods for their syntheses and functionalization, and various applications thereof. For example, novel azaborine-containing biarylcarboxylic acids and biarylcarboxamides are disclosed herein, which provide the opportunity to be used as therapeutic agents in different diseases. The novel azaborine-containing compounds show unique physical and biological properties when compared to their corresponding all-carbon compounds. Also, disclosed herein are substituted 1,2-dihydro- 1,2-azaborine compounds and methods for making the same including methods for the preparation of various substituted azaborines including alkyl, alkenyl, aryl, nitrile, heteroaryl, and fused ring substituents in the presence of B-H, B-Cl, B-O and N-H bonds from Br-substituted azaborines as well as the synthesis of new fused BN- heterocycles.

  本发明提供了新颖的氮硼因化合物、它们的合成及功能化方法，以及它们在各种应用中的用途。例如，本文公开了含有氮硼因的联芳基羧酸和联芳基酰胺，它们提供了作为不同疾病治疗剂使用的机会。与相应的全碳化合物相比，这些新颖的氮硼因化合物显示出独特的物理和生物学特性。此外，本文还公开了取代的1,2-二氢-1,2-氮硼因化合物及其制备方法，包括制备各种取代的氮硼因的方法，这些取代基包括烷基、烯基、芳基、腈、杂芳基和稠合环取代基，在B-H、B-Cl、B-O和N-H键的存在下，从溴取代的氮硼因出发，以及合成新的稠合BN杂环的方法。
• [EN] FASCAPLYSIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE FASCAPLYSINE ET LEUR UTILISATION DANS LE TRAITEMENT D'UN CANCER
  申请人：UNIV MONTFORT

  公开号：WO2009022104A1

  公开（公告）日：2009-02-19

  A method of treating cancer comprising administering a compound of Formula (I), (II) or (III) to a patient.

  一种治疗癌症的方法，包括向患者给予化合物I、II或III的剂量。
• Design, synthesis and biological evaluation of new tryptamine and tetrahydro-β-carboline-based selective inhibitors of CDK4
  作者：Paul R. Jenkins、James Wilson、Daniel Emmerson、Marcos D. Garcia、Matthew R. Smith、Stephen J. Gray、Robert G. Britton、Sachin Mahale、Bhabatosh Chaudhuri

  DOI：10.1016/j.bmc.2008.07.002

  日期：2008.8

  We present the design, synthesis and biological activity of a library of substituted (biphenylcarbonyl)-tryptamine and ( biphenylcarbonyl)-tetrahydro-beta-carboline compounds related to the natural product fascaplysin, as novel inhibitors of CDK4/cyclin D1. We show all these molecules, prepared using the Suzuki-Miyaura reaction, being selective inhibitors of CDK4 over CDK2. The most active compounds have a CDK4 IC50 in the range 9-11 mu M, three of them containing the para-biphenyl plus para-substituents supporting the existence of a pi-stacking pocket within the active site of CDK4. (C) 2008 Published by Elsevier Ltd.
• Biphenyl-4-carboxylic Acid [2-(1<i>H</i>-Indol-3-yl)-ethyl]-methylamide (CA224), a Nonplanar Analogue of Fascaplysin, Inhibits Cdk4 and Tubulin Polymerization: Evaluation of in Vitro and in Vivo Anticancer Activity
  作者：Sachin Mahale、Sandip B. Bharate、Sudhakar Manda、Prashant Joshi、Sonali S. Bharate、Paul R. Jenkins、Ram A. Vishwakarma、Bhabatosh Chaudhuri

  DOI：10.1021/jm5014743

  日期：2014.11.26

  Biphenyl-4-carboxylic acid-[2-(1H-indol-3-yl)-ethyl]-methylamide 1 (CA224) is a nonplanar analogue of fascaplysin (2) that specifically inhibits Cdk4cyclin D1 in vitro. Compound 1 blocks the growth of cancer cells at G(0)/G1 phase of the cell cycle. It also blocks the cell cycle at G(2)/M phase, which is explained by the fact that it inhibits tubulin polymerization. Additionally, it acts as an enhancer of depolymerization for taxol-stabilized tubulin. Western blot analyses of p53-positive cancer cells treated with compound 1 indicated upregulation of p53, p21, and p27 proteins together with downregulation of cyclin B1 and Cdk1. Compound 1 selectively induces apoptosis of SV40 large T-antigen transformed cells and significantly reduces colony formation efficiency, in a dose-dependent manner, of lung cancer cells. It is efficacious at 1/10th of the MTD against human tumors derived from HCT-116 and NCI-H460 cells in SCID mouse models. The promising efficacy of compound 1 in human xenograft models as well as its excellent therapeutic window indicates its potential for clinical development.
• FUNCTIONALIZED AZABORINE COMPOUNDS AND AZABORINE-CONTAINING BIARYLCARBOXAMIDES, AND COMPOSITIONS AND METHODS THEREOF
  申请人：The Trustees of Boston College

  公开号：US20170081347A1

  公开（公告）日：2017-03-23

  The invention provides novel azaborine compounds, methods for their syntheses and functionalization, and various applications thereof. For example, novel azaborine-containing biarylcarboxylic acids and biarylcarboxamides are disclosed herein, which provide the opportunity to be used as therapeutic agents in different diseases. The novel azaborine-containing compounds show unique physical and biological properties when compared to their corresponding all-carbon compounds. Also, disclosed herein are substituted 1,2-dihydro-1,2-azaborine compounds and methods for making the same including methods for the preparation of various substituted azaborines including alkyl, alkenyl, aryl, nitrile, heteroaryl, and fused ring substituents in the presence of B—H, B—Cl, B—O and N—H bonds from Br-substituted azaborines as well as the synthesis of new fused BN-heterocycles.